As the UK’s transition period to leave the European Union (EU) rapidly comes to an end, the Medicines and Healthcare products Regulatory Agency (MHRA) recently published new guidance on how it will regulate medical devices starting in January 2021.
Through this guidance document, the MHRA — which will take over the responsibilities for the UK medical devices market currently undertaken through the EU system — sheds light on how the new UKCA (UK Conformity Assessed) system will operate, including device certification, conformity marking and device registration. The guidance also provides an overview on the different rules that will apply in Great Britain (England, Wales and Scotland), Northern Ireland and the EU.
The proposals outlined in the guidance notice will take effect through legislative changes that will be introduced later in 2020. They are still therefore subject to parliamentary approval.
The UK views this guidance as an opportunity to develop a robust, world-leading regulatory regime for medical devices that prioritises patient safety. It also is taking into consideration international standards and global harmonisation in the development of its future system. Over the next few months, the UK plans to engage with stakeholders within the life sciences and healthcare industries on identifying and prioritising elements of international practice that promote public health and patient safety. Following these meetings, the MHRA will conduct a formal public consultation.
In this blog, we outline the necessary details on these new rules.
Requirements for manufacturing and supplying devices in the UK
Starting from 1st January 2021, the roles and responsibilities of medical device and in vitro diagnostic device (IVD) manufacturers will change. The devices certified under the following Directives/Regulations will in due course, need to conform to the new legislation to stay on the UK market:
- EU Directive 90/385/EEC on active implantable medical devices (AIMDD)
- EU Directive 93/42/EEC on medical devices (MDD)
- EU Directive 98/79/EC on in vitro diagnostic medical devices (IVDD)
- EU Regulation 2017/745 on medical devices (MDR)
- EU Regulation 2017/746 on in vitro diagnostic medical devices (IVDR)
Manufacturers wanting to place medical devices and in vitro diagnostic medical devices (IVDs) on the UK market will first need to register with the MHRA. Here, the agency’s role will be to perform market surveillance of medical devices on the UK market. Additionally, it will be responsible for the designation and monitoring of UK Conformity Assessment Bodies (CABs), which will assess whether products meet the UK Conformity Assessed (UKCA) mark requirements. Existing UK Notified Bodies with designations under the MDD, IVDD or AIMDD will have their designations rolled over automatically, without having to undergo a new designation process.
While CE marking will continue to be used and recognised until 30 June 2023, after this date, companies will need a UKCA mark to sell devices in Great Britain. The grace period for registering includes:
- Four months for Class IIIs and Class IIb implantables, and all active implantable medical devices
- Eight months for other Class IIb and all Class IIa devices
- 12 months for Class I devices (this grace period will not apply to manufacturers of Class I devices and general IVDs that are currently required to register with the MHRA)
The new labelling requirements for UKCA marking will become mandatory from 1st July 2023. Manufacturers based outside the UK will need to establish a UK Responsible Person who will take responsibility for the product.
The UKCA marking alone cannot be used for goods placed on the Northern Ireland market, which require the CE marking or UK (NI) marking.
Post-market surveillance and vigilance
After a medical device has been placed on the UK market, the manufacturer is required to submit vigilance reports to the MHRA when certain incidents occur in the UK that involve the device. In addition, the manufacturer will need to take appropriate safety action when required, ensuring the device meets appropriate standards of safety and performance for as long as it is in use.
Impact to MDR and IVDR
Products sold in Northern Ireland and the EU, where the incoming MDR and IVDR will apply, will still need to carry CE marks after June 2023. UKCA marks can accompany the CE mark on products sold in Northern Ireland, but not on devices placed on the EU market.
What manufacturers should do now
Companies should consider a regulatory partner before making preparations not only to ensure proper documentation, but also to determine which regulatory framework applies best to their product portfolios. While manufacturers have more than two years to gain UKCA marks, the grace period for transition to the mandatory UKCA marking requirements ends less than one year before the end of the MDR transition on 26th May 2024. For already registered devices and IVDs it is even shorter with only 4 to 12 months — depending on the risk class of the product — to comply with MHRA’s requirements, manufacturers should begin planning now.
For more information about planning medical device conformity in the UK market, contact the medical device regulatory team at ICON.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
- EU Regulations
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
-
test insights page
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
-
Oncology
- Paediatrics
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Advanced therapies for rare diseases
-
test insights page
-
Transforming Trials
-
Digitising COAs
-
Linguistic validation of Clinical Outcomes Assessments
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Flexible delivery models
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Supporting a top 10 pharma to transition to Veeva Vault platform
-
Transforming the R&D Model to Sustain Growth
-
Digitising COAs
-
Value Based Healthcare
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
US payers and PROs
-
Blog
-
Videos
-
Webinar Channel